BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares fell 7.8% on Wednesday . The company traded as low as $7.45 and last traded at $7.69. 1,216,058 shares changed hands during trading, an increase of 55% from the average session volume of 782,993 shares. The stock had previously closed at $8.34.

A number of brokerages have weighed in on BCRX. BidaskClub cut shares of BioCryst Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Thursday, January 31st. Zacks Investment Research cut shares of BioCryst Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, April 3rd. JMP Securities lifted their price target on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company a “market outperform” rating in a research report on Tuesday, April 2nd. Finally, Barclays lifted their price target on shares of BioCryst Pharmaceuticals from $6.00 to $8.00 and gave the company an “equal weight” rating in a research report on Tuesday, April 2nd. One equities research analyst has rated the stock with a sell rating, four have assigned a hold rating, six have given a buy rating and one has given a strong buy rating to the company’s stock. BioCryst Pharmaceuticals has a consensus rating of “Buy” and a consensus target price of $11.91.

The company has a current ratio of 1.65, a quick ratio of 1.62 and a debt-to-equity ratio of 0.57. The stock has a market capitalization of $872.60 million, a P/E ratio of -8.08 and a beta of 1.80.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last posted its earnings results on Monday, March 4th. The biotechnology company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.26) by $0.01. The business had revenue of $2.73 million for the quarter, compared to analysts’ expectations of $2.39 million. BioCryst Pharmaceuticals had a negative net margin of 490.25% and a negative return on equity of 175.83%. Research analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -1.19 EPS for the current fiscal year.

In related news, CFO Thomas R. Staab II sold 5,000 shares of the company’s stock in a transaction on Monday, January 28th. The shares were sold at an average price of $9.85, for a total value of $49,250.00. Following the sale, the chief financial officer now directly owns 133,426 shares of the company’s stock, valued at $1,314,246.10. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, VP Lynne Powell sold 6,000 shares of the company’s stock in a transaction on Friday, January 25th. The shares were sold at an average price of $9.60, for a total transaction of $57,600.00. Following the completion of the sale, the vice president now directly owns 6,000 shares in the company, valued at $57,600. The disclosure for this sale can be found here. Insiders sold 30,500 shares of company stock worth $289,925 over the last ninety days. 4.50% of the stock is currently owned by corporate insiders.

Institutional investors and hedge funds have recently bought and sold shares of the stock. Teachers Advisors LLC raised its holdings in BioCryst Pharmaceuticals by 4.1% in the third quarter. Teachers Advisors LLC now owns 294,786 shares of the biotechnology company’s stock valued at $2,249,000 after acquiring an additional 11,682 shares in the last quarter. Bank of New York Mellon Corp raised its holdings in BioCryst Pharmaceuticals by 3.1% in the third quarter. Bank of New York Mellon Corp now owns 420,825 shares of the biotechnology company’s stock valued at $3,211,000 after acquiring an additional 12,544 shares in the last quarter. Paloma Partners Management Co acquired a new stake in BioCryst Pharmaceuticals in the fourth quarter valued at $84,000. BlackRock Inc. raised its holdings in BioCryst Pharmaceuticals by 13.1% in the third quarter. BlackRock Inc. now owns 8,769,856 shares of the biotechnology company’s stock valued at $66,914,000 after acquiring an additional 1,013,905 shares in the last quarter. Finally, Dynamic Technology Lab Private Ltd acquired a new stake in BioCryst Pharmaceuticals in the third quarter valued at $122,000. 91.90% of the stock is currently owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: “BioCryst Pharmaceuticals (BCRX) Stock Price Down 7.8%” was reported by Watch List News and is the property of of Watch List News. If you are reading this story on another website, it was illegally copied and reposted in violation of international trademark and copyright laws. The correct version of this story can be viewed at https://www.watchlistnews.com/biocryst-pharmaceuticals-bcrx-stock-price-down-7-8/2973942.html.

BioCryst Pharmaceuticals Company Profile (NASDAQ:BCRX)

BioCryst Pharmaceuticals, Inc, a biotechnology company, discovers oral and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor, for the treatment of acute uncomplicated influenza under the RAPIVAB, ALPIVAB, RAPIACTA, and PERAMIFLU names; and Mundesine, an oral purine nucleoside phosphorylase inhibitor for peripheral T-cell lymphoma.

Recommended Story: What is the Moving Average Convergence Divergence (MACD) oscillator?

Receive News & Ratings for BioCryst Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioCryst Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.